The USC Norris Comprehensive Cancer Center first participated in the research activities of SWOG in 1987 and was initially funded in 1992. This five-year grant cycle has had increased administrative and academic participation, with maintenance of high clinical and correlative trial entry, commensurate with available SWOG funding and added resources from USC. The major emphases of the USC team are (a) to explore the utility of molecular prognostication with the correlation of specific genes with outcomes of therapy; (b) to investigate novel strategies of chemotherapy for common solid tumors in cancer patients, with a particular emphasis on minority populations and the elderly; (c) to develop novel strategies of prevention of GU and GI cancers. Thus, USC investigators have contributed extensively to SWOG trials and administrative/academic leadership, facilitating the translation of specific themes of investigation to SWOG. Activities have included (a) administrative and scientific leadership (Vice Chairs of GU Committee and GI Committee; cadre membership in Breast, Melanoma and Committee for Women/Special Populations; Scientific Advisory Board; External Advisory Boards of EORTC and Cancer Research UK; Data and Safety Monitoring Committee of SWOG and Chair of DSMC of National Wilms Tumor Study Group; core labs for pharmacology and molecular prognostication studies of GU and GI Committees); (b) educational -Convener of the GU Committee Young Investigator Program & 3 Young Investigator Awards; (c) scientific research agendas translated from USC to SWOG have included the P53 molecular prognostication bladder cancer trial (NCI), international GC vs. GCT bladder CA trial; NCI UO-1 funded pharmacology and molecular prediction of outcome studies in phase II geriatric oncology trials; fluoropyrimidine response correlations in GI cancer and correlative pharmacogenomic studies; (d) continuing high levels of clinical trial accrual with majority of cases from USC itself rather than affiliates; particular progress in clinical trial recruitment within the UCOP population, with the appointment of Dr. Skinner as UCOP PRINCIPAL INVESTIGATOR and active support from USC medical oncologists has led to a nearly 50 GU cases in 2002; major success in minority recruitment with enhancement awards from NCI because of success; (e) multi-disciplinary recruitment of 10 new investigators from Med Onc, Neurology/Neurosurgery, Urology, Pathology, Surgery & Pharmacology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA058882-14
Application #
7050109
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1993-02-01
Project End
2009-12-31
Budget Start
2006-03-29
Budget End
2006-12-31
Support Year
14
Fiscal Year
2006
Total Cost
$258,128
Indirect Cost
Name
University of Southern California
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641
Lara Jr, Primo N; Moon, James; Redman, Mary W et al. (2016) Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer 17:113-8.e1-2
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Bohanes, Pierre; Rankin, Cathryn J; Blanke, Charles D et al. (2015) Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation. Clin Cancer Res 21:1583-90
Lara Jr, Primo N; Moon, James; Redman, Mary W et al. (2015) Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol 10:110-5
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9

Showing the most recent 10 out of 134 publications